Trinity Biotech Plc Stock Performance
| TRIB Stock | USD 0.71 0.03 4.41% |
The entity has a beta of 0.52, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Trinity Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Trinity Biotech is expected to be smaller as well. Trinity Biotech plc right now has a risk of 11.75%. Please validate Trinity Biotech sortino ratio, skewness, price action indicator, as well as the relationship between the potential upside and rate of daily change , to decide if Trinity Biotech will be following its existing price patterns.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Trinity Biotech plc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat weak forward indicators, Trinity Biotech may actually be approaching a critical reversion point that can send shares even higher in April 2025. ...more
Last Split Factor 1:5 | Dividend Date 2015-07-01 | Ex Dividend Date 2015-06-05 | Last Split Date 2024-02-23 |
1 | StockNews.com Initiates Coverage on Trinity Biotech | 02/07/2025 |
2 | Trinity Capital Inc Q4 2024 Earnings Report Preview What To Look For | 02/25/2025 |
3 | Trinity Industries, Inc.s institutional investors lost 4.4 percent last week but have benefitted from longer-term gains | 03/05/2025 |
4 | Super League Wakefield Trinity impress in victory at Warrington | 03/10/2025 |
5 | Becky Salato Named North Coast Woman Of The Year | 03/11/2025 |
6 | Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring -- Appoints Barclays ... | 03/13/2025 |
7 | Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares and Nasdaq Minimum Bi... | 03/14/2025 |
8 | Trinity Consultants Acquires Jaffe Holden | 03/18/2025 |
9 | Trinity Capital Inc. Declares Cash Dividend of 0.51 per Share for the First Quarter of 2025 | 03/19/2025 |
10 | Trinity Biotech files to sell 4.29M American Depositary Shares for holders | 03/21/2025 |
| Begin Period Cash Flow | 6.6 M |
Trinity |
Trinity Biotech Relative Risk vs. Return Landscape
If you would invest 90.00 in Trinity Biotech plc on December 23, 2024 and sell it today you would lose (19.00) from holding Trinity Biotech plc or give up 21.11% of portfolio value over 90 days. Trinity Biotech plc is currently generating 0.1385% in daily expected returns and assumes 11.7453% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Trinity, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Trinity Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Trinity Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Trinity Biotech plc, and traders can use it to determine the average amount a Trinity Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0118
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | TRIB |
| Negative Returns |
Estimated Market Risk
| 11.75 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.14 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Trinity Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Trinity Biotech by adding Trinity Biotech to a well-diversified portfolio.
Trinity Biotech Fundamentals Growth
Trinity Stock prices reflect investors' perceptions of the future prospects and financial health of Trinity Biotech, and Trinity Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Trinity Stock performance.
| Return On Equity | -19.13 | ||||
| Return On Asset | -0.0819 | ||||
| Profit Margin | (0.34) % | ||||
| Operating Margin | (0.15) % | ||||
| Current Valuation | 110.35 M | ||||
| Shares Outstanding | 27.52 M | ||||
| Price To Earning | 31.00 X | ||||
| Price To Book | 5.11 X | ||||
| Price To Sales | 0.33 X | ||||
| Revenue | 56.83 M | ||||
| Gross Profit | 21.13 M | ||||
| EBITDA | (24.1 M) | ||||
| Net Income | (24.02 M) | ||||
| Cash And Equivalents | 10.01 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 67.43 M | ||||
| Current Ratio | 3.66 X | ||||
| Book Value Per Share | (2.54) X | ||||
| Cash Flow From Operations | (11.56 M) | ||||
| Earnings Per Share | (2.25) X | ||||
| Market Capitalization | 19.48 M | ||||
| Total Asset | 59.44 M | ||||
| Retained Earnings | (48.64 M) | ||||
| Working Capital | 24.01 M | ||||
| Current Asset | 151 M | ||||
| Current Liabilities | 21 M | ||||
About Trinity Biotech Performance
By analyzing Trinity Biotech's fundamental ratios, stakeholders can gain valuable insights into Trinity Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Trinity Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Trinity Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 175.16 | 164.57 | |
| Return On Tangible Assets | (0.50) | (0.48) | |
| Return On Capital Employed | (0.55) | (0.52) | |
| Return On Assets | (0.36) | (0.35) | |
| Return On Equity | 0.90 | 0.95 |
Things to note about Trinity Biotech plc performance evaluation
Checking the ongoing alerts about Trinity Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Trinity Biotech plc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Trinity Biotech plc had very high historical volatility over the last 90 days | |
| Trinity Biotech plc has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 56.83 M. Net Loss for the year was (24.02 M) with profit before overhead, payroll, taxes, and interest of 21.13 M. | |
| Trinity Biotech plc currently holds about 10.01 M in cash with (11.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41. | |
| Roughly 12.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from seekingalpha.com: Trinity Biotech files to sell 4.29M American Depositary Shares for holders |
- Analyzing Trinity Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Trinity Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Trinity Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Trinity Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Trinity Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Trinity Biotech's stock. These opinions can provide insight into Trinity Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Trinity Stock analysis
When running Trinity Biotech's price analysis, check to measure Trinity Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trinity Biotech is operating at the current time. Most of Trinity Biotech's value examination focuses on studying past and present price action to predict the probability of Trinity Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trinity Biotech's price. Additionally, you may evaluate how the addition of Trinity Biotech to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |